TENX - Tenax Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.1900
+0.0400 (+3.48%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.1500
Open1.1300
Bid1.00 x 800
Ask1.21 x 1000
Day's Range1.1300 - 1.4000
52 Week Range1.0300 - 12.6300
Volume919,482
Avg. Volume315,458
Market Cap1.744M
Beta (3Y Monthly)0.64
PE Ratio (TTM)N/A
EPS (TTM)-4.12
Earnings DateJul 27, 2015 - Aug 6, 2015
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.25
Trade prices are not sourced from all markets
  • Business Wire3 days ago

    Tenax Therapeutics Announces Closing of $10 Million Underwritten Offering

    Tenax Therapeutics, Inc. (TENX) (“Tenax” or the “Company”), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced the closing of an underwritten offering for gross proceeds of approximately $10 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Tenax. The offering was comprised of 5,181,346 units, priced at an offering price of $1.93 per unit, with each unit consisting of one share of Series A convertible preferred stock, having a conversion price of $1.93, a two-year warrant to purchase one share of common stock with an exercise price of $1.93 per share, and a five-year warrant to purchase one share of common stock with an exercise price of $1.93 per share.

  • Business Wire8 days ago

    Tenax Therapeutics Announces Pricing of $10 Million Underwritten Offering

    Tenax Therapeutics, Inc. (TENX) (“Tenax” or the “Company”), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced the pricing of an underwritten offering for gross proceeds of approximately $10 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Tenax. The offering is comprised of 5,181,346 units, priced at an offering price of $1.93 per unit, with each unit consisting of one share of Series A convertible preferred stock, having a conversion price of $1.93, a two-year warrant to purchase one share of common stock with an exercise price of $1.93 per share, and a five-year warrant to purchase one share of common stock with an exercise price of $1.93 per share.

  • Zacks Small Cap Research19 days ago

    TENX: We Have Liftoff: HELP Site Activated

    During the third quarter Tenax Therapeutics, Inc. (TENX) continued to prepare its Phase II levosimendan trial for PH-HFpEF enrollment. General and administrative expenses tipped the scale at $1.2 million, rising 13% compared to 3Q:17.

  • TheStreet.com23 days ago

    Heat Biologics Takes Beating After Pricing $12 Million Stock Offering

    The North Carolina-based biopharmaceutical company expected to offer 8 million shares of common stock and warrants to purchase 4 million shares of common stock with an expected combined price of $1.50. The money raised would be used to further develop its so-called T-cell immunotherapies that if successful would activate a patient's immune system to fight off cancer. , a London-based clinical-stage biopharmaceutical company, slipped 1.76% to $7.82, while New York-based Axsome Therapeutics, Inc.

  • Business Wire26 days ago

    Tenax Therapeutics Activates First Clinical Research Site for Phase 2 Pulmonary Hypertension Clinical Trial

    Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that Stanford University School of Medicine has been activated as the first clinical research site for the Company’s Phase 2 trial designed to evaluate levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The study is also known as the H-E-L-P Trial (Hemodynamic Evaluation of Levosimendan in Patients with PH-HFpEF) and is expected to enroll a total of 36 PH-HFpEF patients at up to approximately 12-15 major research institutions across the US. Anthony DiTonno, CEO of Tenax Therapeutics, Inc., stated, “We are very excited to have activated our first site for the HELP trial.

  • Zacks Small Cap Researchlast month

    TENX: Tenax S-1 Filing

    By John Vandermosten, CFA NASDAQ:TENX On November 6th Tenax Therapeutics (NASDAQ:TENX) filed an S-1 proposing to raise $10 million in equity capital to support operations into 2020. While the funds are ...

  • Simply Wall St.2 months ago

    How Should You Think About Tenax Therapeutics Inc’s (NASDAQ:TENX) Risks?

    Anyone researching Tenax Therapeutics Inc (NASDAQ:TENX) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Read More...

  • Business Wire3 months ago

    Tenax Therapeutics to Present at Upcoming Investor Conferences

    For more information, please visit the company website at www.tenaxthera.com. Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market.

  • Zacks Small Cap Research3 months ago

    TENX: 3Q Start to Pulmonary Hypertension Trial

    By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Second Quarter 2018 Review In January, Tenax Therapeutics, Inc. (NASDAQ:TENX) announced its plan to advance the development of levosimendan ...

  • Business Wire4 months ago

    Tenax Therapeutics to Present at H.C. Wainwright 20th Annual Global Investment Conference

    Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that the Company will participate in the H.C. Wainwright 20th Annual Global Investment Conference, which takes place September 4-6, in New York. Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market. The Company has a world-class scientific team including recognized global experts in pulmonary hypertension.

  • Business Wire4 months ago

    Tenax Therapeutics Announces New Clinical Study Publication Results Indicate Levosimendan Offers Renal Protective Benefits to Heart Failure Patients

    Tenax Therapeutics, Inc. (TENX) today announced the results of a new study titled "Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment: A Randomized Double‐Blind Controlled Trial” were published in the August 21, 2018 issue of the Journal of the American Heart Association (https://www.ahajournals.org/doi/full/10.1161/JAHA.117.008455). The results indicate that levosimendan offers unique renal protective benefits to patients who have heart failure and coexisting impairment of their kidney function.

  • Has Tenax Therapeutics Inc (NASDAQ:TENX) Improved Earnings Growth In Recent Times?
    Simply Wall St.6 months ago

    Has Tenax Therapeutics Inc (NASDAQ:TENX) Improved Earnings Growth In Recent Times?

    For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Tenax Therapeutics Inc’s (NASDAQ:TENX) track record on a high level, toRead More...

  • Zacks Small Cap Research6 months ago

    TENX: Tenax 1Q:18 Results

    By John Vandermosten, CFA NASDAQ:TENX READ THE FULL RESEARCH REPORT First Quarter 2018 Review 2018 began a new chapter for Tenax Therapeutics (NASDAQ:TENX). In January, Tenax announced its plan to advance ...

  • Business Wire6 months ago

    Tenax Therapeutics Announces Appointment of Anthony A. DiTonno as CEO

    Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced the Company has selected board member Anthony A. DiTonno to be its next Chief Executive Officer, effective June 1, 2018. Michael Jebsen, Tenax’s current Interim Chief Executive Officer and Chief Financial Officer, will remain serving as Tenax’s Chief Financial Officer.

  • Business Wire6 months ago

    Tenax Therapeutics Announces Study Design for Phase 2 Trial of Levosimendan in PH-HFpEF Patients

    Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on providing products to address conditions with significant unmet medical needs, today announced the registration of their Phase 2 clinical trial in the use of levosimendan for treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF) on ClinicalTrials.gov. The Phase 2 PH-HFpEF study is a multi-center, double blind, randomized, placebo-controlled clinical trial that is testing the hypothesis that chronic, intermittent doses of levosimendan will significantly improve hemodynamic measures of exercise performance in patients suffering from Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.

  • Why You Need To Look At This Factor Before Buying Tenax Therapeutics Inc (NASDAQ:TENX)
    Simply Wall St.7 months ago

    Why You Need To Look At This Factor Before Buying Tenax Therapeutics Inc (NASDAQ:TENX)

    If you are looking to invest in Tenax Therapeutics Inc’s (NASDAQ:TENX), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...

  • How Do Analysts See Tenax Therapeutics Inc (NASDAQ:TENX) Performing In The Next Couple Of Years?
    Simply Wall St.8 months ago

    How Do Analysts See Tenax Therapeutics Inc (NASDAQ:TENX) Performing In The Next Couple Of Years?

    Tenax Therapeutics Inc’s (NASDAQ:TENX) latest earnings announcement in December 2017 confirmed that losses became smaller relative to the prrior year’s level – great news for investors Today I want toRead More...

  • Zacks Small Cap Research8 months ago

    TENX: New Indication for Levosimendan

    Levosimendan is a calcium sensitizer and K-ATP channel activator that can improve systolic and diastolic function of the heart as well as provide vasodilatory effects through its ability to relax vascular smooth muscle. This mechanism of action has been shown to lead to important improvements in cardiovascular hemodynamics in previous heart failure studies, including increased cardiac output and reduction in pulmonary capillary wedge pressure which could be very helpful in correcting the reduced cardiac output and pulmonary congestion often seen in PH-HFpEF patients. It is also important to note that Levosimendan has been shown to improve right heart function as well as reduce pulmonary vascular resistance in various patient populations.

  • Benzinga8 months ago

    Finding Breakouts And Avoiding Fakeouts In A Market At War With Itself

    After a few weeks of travel culminating in last week’s Inner Circle Conference in Orlando , I’ve returned to a market filled with extremes . There is a lot of optimism and a healthy dose of anxiety riling ...

  • Benzinga8 months ago

    Benzinga's Top Analyst Calls From April 5, 2018

    These headlines first appeared on Benzinga Pro . DA Davidson says Cadence Design Systems Inc (NASDAQ: CDNS )’s business strength is not reflected in its weak stock performance, upgrades from Neutral to ...

  • ACCESSWIRE8 months ago

    This $3 Medical Device Stock be Worth $9-14 with Impending Product Launch

    - Cardiology interventions and diagnostics are a big market, and the new field of remote monitoring, for arrhythmias and heart trouble, is a rapidly expanding component. Better remote monitoring technology ...

  • Tenax Therapeutics Inc’s (NASDAQ:TENX) Shift From Loss To Profit
    Simply Wall St.8 months ago

    Tenax Therapeutics Inc’s (NASDAQ:TENX) Shift From Loss To Profit

    Tenax Therapeutics Inc’s (NASDAQ:TENX): Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in theRead More...

  • Business Wire8 months ago

    Tenax Therapeutics Announces Results of Pre-IND Meeting with FDA for Phase 2 Study of Levosimendan in PH-HFpEF Patients

    Tenax Therapeutics, Inc.  , a specialty pharmaceutical company focused on providing products to address conditions with significant unmet medical needs, today announced the results of its pre-Investigational New Drug meeting with the United States Food & Drug Administration , where the FDA addressed the Company’s questions and provided guidance on its upcoming Phase 2 clinical trial in the use of levosimendan ...